Fat Pill Clears Hurdle
Stocks are responding to the deal with Iran, as Orexigen clears safety hurdle for its obesity drug Contrave. Adam Feuerstein gives details.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
